Lindsey Vandyke, DO
Endocrinology, Diabetes & Metabolism · Mansfield, TXNPI 1871998880
Payments from drug & device makers
Across 409 payments — averaging $52.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuity Medical Inc$6K
- AstraZeneca$5K
- Intuitive Surgical$3K
- Novo Nordisk$2K
- Lilly USA, LLC$741
- Amgen$438
- plus $4K from 34 others
What the payments were for
- Speaking & faculty fees$10,90050%
- Travel & lodging$1,4837%
- Food & beverage$8,92141%
- Education$2561%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuity Medical Inc | 14 | $5,975 |
| AstraZeneca(2 entities) | 57 | $5,147 |
| Intuitive Surgical | 7 | $3,133 |
| Novo Nordisk | 85 | $1,692 |
| Lilly USA, LLC | 37 | $741 |
| Amgen(2 entities) | 17 | $438 |
| Bayer | 18 | $434 |
| Medtronic(2 entities) | 12 | $426 |
| Mannkind Corporation | 21 | $415 |
| Senseonics, Incorporated | 1 | $400 |
| Novartis | 13 | $334 |
| Insulet Corporation | 26 | $284 |
| Dexcom, Inc. | 10 | $196 |
| Tandem Diabetes Care, Inc. | 8 | $185 |
| Corcept Therapeutics | 7 | $179 |
| BETA Bionics, Inc. | 4 | $175 |
| Cequr Corporation | 4 | $164 |
| Abbott | 7 | $160 |
| Radius Health, Inc. | 6 | $128 |
| Sanofi-aventis U.S. LLC | 6 | $112 |
| Zealand Pharma US, Inc. | 6 | $97 |
| Vistapharm, Inc. | 5 | $76 |
| Xeris Pharmaceuticals, Inc. | 4 | $73 |
| Currax Pharmaceuticals LLC | 5 | $70 |
| Merck | 4 | $70 |
| Valeritas, Inc. | 2 | $70 |
| Ascensia Diabetes Care US Inc. | 4 | $66 |
| Rhythm Pharmaceuticals, Inc. | 2 | $51 |
| Boehringer Ingelheim | 2 | $42 |
| IBSA Pharma Inc. | 2 | $41 |
| Ascendis Pharma Endocrinology Inc | 2 | $36 |
| Halozyme Inc | 2 | $35 |
| Orthofix Medical, Inc. | 1 | $29 |
| Sequel Med Tech, LLC | 1 | $28 |
| GRT US Holding, Inc. | 1 | $24 |
| Companion Medical, Inc. | 2 | $22 |
| Antares Pharma, Inc. | 1 | $20 |
| AbbVie | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Pogo Automatic Blood Glucose Monitoring System$5,823
- FARXIGA$4,205
- Da Vinci Surgical System$3,103
- Eversense$400
- iLet Bionic Pancreas$373
- Ozempic$358
- Kerendia$125
- Minimed 670G System$119
- Wegovy$116
- EVENITY$108
- INPEN SMART INSULIN DELIVERY SYSTEM$106
How this compares
$21,619 in reported general payments places this provider in the 75th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $222,328 |
| MounjaroTirzepatide | 132 | $137,424 |
| FarxigaDapagliflozin Propanediol | 76 | $91,057 |
| JardianceEmpagliflozin | 78 | $88,015 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 76 | $68,624 |
| Tresiba Flextouch U-100Insulin Degludec | 119 | $68,534 |
| JanuviaSitagliptin Phosphate | 36 | $24,609 |
| LyumjevInsulin Lispro-Aabc | 23 | $22,803 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $20,371 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $17,529 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 21 | $13,900 |
| Repatha SureclickEvolocumab | 14 | $11,595 |
| BaqsimiGlucagon | 17 | $8,119 |
| Gvoke Hypopen 2-PackGlucagon | 12 | $7,915 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 11 | $7,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,692 | $224,827176 claims |
| Lilly USA, LLCMounjaro, Lyumjev, Baqsimi | $741 | $168,346172 claims |
| AstraZenecaFarxiga | $5,147 | $91,05776 claims |
| Boehringer IngelheimJardiance | $42 | $88,01578 claims |
| MerckJanuvia | $70 | $24,60936 claims |
| Cequr CorporationCequr Simplicity | $164 | $7,37511 claims |
| AbbVieSynthroid | $19 | $1,54318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Mansfield
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.